Share this article
Share this article
THOUSAND OAKS, Calif., Feb. 16, 2021 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for sotorasib for the treatment of patients with
KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), following at least one prior systemic therapy.
The FDA grants Priority Review to applications for medicines that offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious conditions, or enhancing patient compliance. Based on the Priority Review designation, the Prescription Drug User Fee Action (PDUFA) date for sotorasib is Aug. 16, 2021, which is four months earlier than the standard review cycle.
/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing a drug to treat cancers with the greatest medical need.
ObvioHealth Announces Next Generation Virtual Research Platform and Ecosystem
Seamless integration of ObvioHealth patient-friendly app with digital device partners enables frictionless remote monitoring of patient vitals from home
News provided by
Share this article
Share this article
NEW YORK, Feb. 16, 2021 /PRNewswire/ ObvioHealth, a global Virtual Research Organization (VRO), announces its next generation platform offering enhanced remote patient monitoring capabilities for the company s end-to-end decentralized clinical trial solutions.
ObvioHealth s decentralized platform and smartphone app have been designed from inception with patients in mind. To date, dozens of ObvioHealth virtual trials have delivered best in class metrics for patient recruitment time, medication adherence and retention. The platform upgrade builds on this momentum, integrating an ecosystem of FDA-cleared devices to support remote monitoring through seamless connections to its patient-centric app.
Share this article
Share this article
BRASÍLIA, Brazil, Feb. 16, 2021 /PRNewswire/ Over the past several years, worldwide demand for healthy and sustainable foods has been on the rise; just consider that the global health and wellness food market was valued at USD $701.1 billion in 2016 and is expected to reach USD $811.82 billion in 2021. Against the backdrop of these shifting eating habits and values, Brazil is rising to the challenge to meet U.S. consumers demands over the coming year.
As the COVID-19 pandemic continues to shed light on the importance of health and immunity, in addition to bringing conversations about long-term sustainability to the forefront, consumers interest in nutritious and sustainable food products has been even further amplified. In 2020, nearly 90% of American adults sought out food with functional health benefits, and 65% of consumers were looking to have a positive impact on the environment through their daily habits, including their diets.
Cornbread Hemp Introduces USDA Organic Topical CBD Product Line
Two CBD lotions and a CBD balm stick make an all-organic topical product line
News provided by
Share this article
Share this article
LOUISVILLE, Ky., Feb. 16, 2021 /PRNewswire/ Cornbread Hemp announced today the re-formulation of their best-selling CBD lotions, now with all organic ingredients. That means that all of Cornbread Hemp s CBD topicals and CBD creams now bear the USDA organic seal, just like their CBD oils.
Cornbread Hemp s full line of CBD topical products are now USDA certified organic, including their CBD Balm, CBD Lotion for Skin, and CBD Lotion + Menthol.